TL;DR
While Eli Lilly maintains its overall dominance in the obesity market with injectable tirzepatide, Novo Nordisk has firmly captured the oral market with a massive lead for oral Wegovy over Lilly's Foundayo. Meanwhile, the long-term competitive horizon is shifting rapidly as generic challengers target Lilly's core patents, and clinical-stage rivals like Viking Therapeutics diversify into alternative mechanisms like amylin.
Novo Nordisk Establishes Dominance in the Oral Weight-Loss Segment
Novo Nordisk is translating its first-mover advantage and household brand recognition into near-total control of the newly formed oral GLP-1 market, leaving Eli Lilly's rival pill struggling for traction.
"According to IQVIA prescription data compiled for the week ending July 17, 2026, oral Wegovy is maintaining a high-volume trajectory... capturing 89% of the oral weight-loss pill prescription volume and successfully fending off Eli Lilly's rival pill, Foundayo..."
— [novo-nordisk-q1-2026-oral-wegovy-cagrisema
]
This dominance is reinforced by structural advantages, as detailed by the Wall Street Journal, including Novo's immediate day-one formulary coverage and superior clinical trial efficacy of 16.6% weight loss compared to Foundayo's 12.4% novo-nordisk-q1-2026-oral-wegovy-cagrisema. For Lilly, reversing this trend will require overcoming delayed insurance coverage and the steep challenge of building a new consumer brand from scratch lilly-q1-2026-earnings-foundayo-launch
+1.
What to watch: Watch Novo Nordisk's upcoming Q2 earnings call on August 5, 2026, where analysts will heavily scrutinize oral Wegovy's long-term patient retention rates novo-nordisk-q1-2026-oral-wegovy-cagrisema.
Generic Challengers Move to Crack the Tirzepatide Monopoly
The long-term financial moat protecting the industry's most lucrative injectables is facing its first major structural challenge as global generic giants coordinate regulatory filings to break Eli Lilly's patents.
"Sandoz is building its GLP-1 development platform and this submission reflects true in-house innovation. It represents a key first step in our efforts to bring this medicine to market and underscores our ambition to increase competition and expand affordability..."
— [lilly-q1-2026-earnings-foundayo-launch+1]
By filing Abbreviated New Drug Applications with Paragraph IV patent challenges, generic manufacturers like Sandoz and Hybio Pharmaceutical are forcing Lilly into defensive litigation lilly-q1-2026-earnings-foundayo-launch+1. While Lilly's patents are technically valid until 2036, these aggressive legal maneuvers threaten to significantly accelerate the timeline for low-cost alternatives lilly-q1-2026-earnings-foundayo-launch+1.
What to watch: Watch for Eli Lilly to initiate patent infringement lawsuits against Sandoz and Hybio, which will trigger an automatic 30-month FDA approval stay on generic tirzepatide lilly-q1-2026-earnings-foundayo-launch+1.
Clinical-Stage Contenders Diversify to Avoid the GLP-1 Bottleneck
Mid-tier biotechnology companies are rapidly expanding into alternative metabolic pathways like amylin to create differentiated combination therapies and bypass the crowded GLP-1 landscape.
"Therapies that target amylin and calcitonin receptors may potentially be used alone or in combination with GLP-1 or dual GLP-1/GIP agonists to improve the induction of weight loss as well as for longer-term weight management."
— [viking-therapeutics-vktx-ma-target-oral-vk2735-2026
]
Viking Therapeutics' initiation of a Phase 1 trial for its amylin agonist VK3019 represents a strategic hedge viking-therapeutics-vktx-ma-target-oral-vk2735-2026. By developing a second metabolic pathway alongside its core dual GLP-1/GIP agonist VK2735, the company aims to offer flexible weight-loss induction and maintenance options that stand out from existing monotherapies viking-therapeutics-vktx-ma-target-oral-vk2735-2026.
What to watch: Watch for Viking to report results from its Phase 1 study exploring various VK2735 maintenance dosing regimens in the third quarter of 2026 viking-therapeutics-vktx-ma-target-oral-vk2735-2026.
What surprised us
- Novo's absolute crushing of Lilly in the oral market. While Lilly maintains a dominant 59.5% share of the overall U.S. obesity market through injectables, Novo's oral Wegovy has completely monopolized the oral segment, commanding an 89% market share lilly-q1-2026-earnings-foundayo-launch+1.
- The speed of the generic onslaught. Sandoz and Hybio filing abbreviated applications for tirzepatide generic alternatives so early in the drug's commercial life shows that generic manufacturers are moving at unprecedented speed to target the GLP-1 gold rush lilly-q1-2026-earnings-foundayo-launch+1.
- Viking's aggressive dual-track oral strategy. Beyond its subcutaneous trials, Viking is planning to initiate a Phase 3 trial for its oral tablet formulation of VK2735 in late 2026, positioning itself to potentially deliver the first oral dual GLP-1/GIP agonist on the market viking-therapeutics-vktx-ma-target-oral-vk2735-2026.
Open threads worth a vote
Since last time
- Promoted
- Novo Nordisk’s Oral Dominance: Previously a minor point about pipeline shifts, this is now the central narrative of the oral market.
- Viking Therapeutics: Moved from an open thread to a core section on metabolic diversification.
- Escalated
- Eli Lilly’s Injectable Dominance: While the narrative has shifted, Lilly’s 59.5% share of the overall U.S. obesity market remains the foundational baseline for the industry.
- Demoted
- Eli Lilly’s Foundayo: Previously the headline of the oral market, it is now discussed as a challenger struggling to gain traction against Novo.
- Disappeared
- Novo Nordisk’s Supply Chain/Margin Squeeze: No longer a focus of current reporting.
- CagriSema Clinical Failure: The REDEFINE trial results are no longer highlighted.
- Kailera/HRS-7535: The oral small-molecule tolerability issues are absent from this briefing.
- 2027 U.S. Price Cuts: No longer mentioned as an immediate strategic driver.
- Unchanged
- Eli Lilly’s Injectable Market Position: The core dynamic of Lilly leading the injectable space remains the constant against which new threats are measured.
Novo Nordisk Establishes Dominance in the Oral Weight-Loss Segment (Promoted)
Novo Nordisk has effectively neutralized the initial hype surrounding Eli Lilly's Foundayo, translating its first-mover advantage into near-total control of the oral segment.
"According to IQVIA prescription data compiled for the week ending July 17, 2026, oral Wegovy is maintaining a high-volume trajectory... capturing 89% of the oral weight-loss pill prescription volume and successfully fending off Eli Lilly's rival pill, Foundayo..."
— [novo-nordisk-q1-2026-oral-wegovy-cagrisema]
Novo’s lead is driven by immediate day-one formulary coverage and superior clinical trial efficacy (16.6% weight loss vs. Foundayo’s 12.4%). Lilly is currently struggling to overcome delayed insurance coverage and the difficulty of building a new consumer brand from scratch lilly-q1-2026-earnings-foundayo-launch+1.
What to watch: Novo Nordisk's Q2 earnings call on August 5, 2026, specifically regarding oral Wegovy's long-term patient retention rates novo-nordisk-q1-2026-oral-wegovy-cagrisema.
Generic Challengers Move to Crack the Tirzepatide Monopoly (New)
The financial moat protecting Eli Lilly’s core injectable business is facing its first structural challenge. Generic giants are moving to break patent protections well ahead of the 2036 expiration.
"Sandoz is building its GLP-1 development platform and this submission reflects true in-house innovation. It represents a key first step in our efforts to bring this medicine to market and underscores our ambition to increase competition and expand affordability..."
— [lilly-q1-2026-earnings-foundayo-launch+1]
By filing Abbreviated New Drug Applications with Paragraph IV challenges, Sandoz and Hybio Pharmaceutical are forcing Lilly into defensive litigation.
What to watch: Eli Lilly’s anticipated patent infringement lawsuits, which will trigger an automatic 30-month FDA approval stay on generic tirzepatide lilly-q1-2026-earnings-foundayo-launch+1.
Clinical-Stage Contenders Diversify to Avoid the GLP-1 Bottleneck (Promoted)
Mid-tier biotech companies are pivoting toward alternative metabolic pathways, specifically amylin, to create combination therapies that differentiate them from the crowded GLP-1 field.
"Therapies that target amylin and calcitonin receptors may potentially be used alone or in combination with GLP-1 or dual GLP-1/GIP agonists to improve the induction of weight loss as well as for longer-term weight management."
— [viking-therapeutics-vktx-ma-target-oral-vk2735-2026]
Viking Therapeutics is leading this charge, initiating a Phase 1 trial for its amylin agonist VK3019 as a strategic hedge alongside its dual GLP-1/GIP agonist VK2735 viking-therapeutics-vktx-ma-target-oral-vk2735-2026.
What to watch: Viking's Phase 1 results exploring VK2735 maintenance dosing regimens in Q3 2026 viking-therapeutics-vktx-ma-target-oral-vk2735-2026.
Eli Lilly’s Injectable Dominance (Unchanged)
Despite the oral market and generic patent challenges, Eli Lilly maintains a dominant 59.5% share of the overall U.S. obesity market through its injectable tirzepatide portfolio lilly-q1-2026-earnings-foundayo-launch+1.
What surprised us
- Novo's absolute crushing of Lilly in the oral market. [UPDATED] While Lilly holds the injectable market, Novo's oral Wegovy has monopolized the oral segment with an 89% share, a sharp reversal from the early Foundayo launch hype lilly-q1-2026-earnings-foundayo-launch+1.
- The speed of the generic onslaught. [NEW] Sandoz and Hybio filing abbreviated applications for tirzepatide so early in the drug's lifecycle signals an aggressive, unprecedented push by generic manufacturers lilly-q1-2026-earnings-foundayo-launch+1.
- Viking's aggressive dual-track oral strategy. [UPDATED] Viking is planning a Phase 3 trial for its oral VK2735 tablet in late 2026, aiming to be the first to market with an oral dual GLP-1/GIP agonist viking-therapeutics-vktx-ma-target-oral-vk2735-2026.
Open threads
- Closed: Novo Nordisk Ozempic and Wegovy 2027 U.S. Price Cuts (No longer a focus).
- Absorbed: Novo Nordisk Q2 2026 Earnings and Oral Wegovy Retention Rates (Now in "What to watch" in the Oral section).
- Absorbed: Viking Therapeutics Oral VK2735 Phase 3 Trial Initiation (Now in "What surprised us").